fda compounding semaglutide warning letters september 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines FDA Issues Warning Letters to

April 1, 2025

Keshavarzian, A

The new label includes references to some of those postmarketing risks, including intestinal obstruction, [and] severe constipation including fecal impaction. Some patients who took Zepbound have filed lawsuits, accusing Eli Lilly of failing to properly warn them that Zepbound could increase their risk of severe gut problems, including bowel obstructions, pancreatitis, and gastroparesis

However, caution is warranted - GLP-1 agonists can also cause periodic loose stools or gastric upset (e.g

Adding a caloric deficit on top of declining estrogen and progesterone creates a fatigue picture that can feel overwhelming

Formula stabilized using MSSPT (Molecular Structure Stabilization Process Technology) maintains structural integrity and bioactivity even during temporary temperature deviations above 8C during transportation